# Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1

> **NCT03721679** · PHASE1,PHASE2 · TERMINATED · sponsor: **Oncovir, Inc.** · enrollment: 7 (actual)

## Conditions studied

- Solid Cancer

## Interventions

- **BIOLOGICAL:** Poly-ICLC combination treatment with aPD-1 (Nivolumab or Pembrolizumab) or aPD-L1 (Atezolizumab or Durvalumab) over 6 months

## Key facts

- **NCT ID:** NCT03721679
- **Lead sponsor:** Oncovir, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-09-25
- **Primary completion:** 2021-01-26
- **Final completion:** 2021-01-26
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Recruiting target patients is intermittent making it impracticable to enroll the required study sample. The administrative responsibilities have been met with extraordinary challenges. Current funding does not match the incurring costs.
- **Last updated:** 2021-02-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03721679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03721679, "Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03721679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*